{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:23:12Z","timestamp":1790133792084,"version":"4.0.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This phase 2 study evaluated the efficacy and safety of combining acalabrutinib and lenalidomide with either rituximab (ALR) or obinutuzumab (ALO), with longitudinal minimal residual disease (MRD) monitoring in frontline MCL treatment. The primary objective was molecular complete response (CR) after 12 cycles of induction, defined by Lugano criteria, and undetectable MRD of &amp;lt;10\u22126 (uMRD6) by clonoSEQ. Secondary objectives included safety, responses, and survival. Exploratory objectives included tumor mutation profiles and cell-free DNA (cfDNA) by cancer personalized profiling by deep sequencing. Patients in uMRD6 molecular CR were eligible for discontinuation of acalabrutinib plus lenalidomide after 24 cycles; all patients received a minimum of 36 cycles of anti-CD20 antibody treatment. In the ALR cohort, grade 3\/4 hematologic toxicities included neutropenia (38%), thrombocytopenia (4%), and anemia (4%). Nonhematologic toxicities included rash (42%), fatigue (4%), nausea (4%), and vomiting (4%). The overall response rate (ORR) was 100%, CR rate was 83%, and molecular CR rate was 67% after 12 cycles of induction, with best molecular CR at 83%. At a median follow-up of 53 months (range, 46-60), the 4-year overall survival (OS) and progression-free survival (PFS) for ALR were 91% and 76%, respectively. TP53 mutations were adversely associated with PFS (P = .026). For ALO, ORR, CR, and molecular CR were 90% after induction, and 2-year OS and PFS were both at 100%. Longitudinal cfDNA analysis in ALR revealed clonal evolution during response and progression. This safe and active regimen is feasible as a time-limited initial therapy for patients with MCL and warrants further evaluation in response-adapted strategy. This trial was registered at www.ClinicalTrials.gov as NCT03863184.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017760","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T18:01:31Z","timestamp":1764093691000},"page":"1381-1394","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-1360","authenticated-orcid":false,"given":"Jia","family":"Ruan","sequence":"first","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David A.","family":"Bond","sequence":"additional","affiliation":[{"name":"2The Ohio State University Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[{"name":"3Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Rutherford","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Gribbin","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-6452","authenticated-orcid":false,"given":"Zhengming","family":"Chen","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-8761","authenticated-orcid":false,"given":"Bhavneet","family":"Bhinder","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tam","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"4Institute of Oncology Research, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Xiang","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Hobbie","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Harbhajan","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejasvi K.","family":"Sahni","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-7178","authenticated-orcid":false,"given":"Gui Z.","family":"Chen","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0328-8359","authenticated-orcid":false,"given":"Michael","family":"Sigouros","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-0864","authenticated-orcid":false,"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"2The Ohio State University Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"26","key":"2026022411385138300_bib1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2026022411385138300_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"2026022411385138300_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023022353","article-title":"Treatment of relapsed\/refractory MCL","volume":"145","author":"Silkenstedt","year":"2025","journal-title":"Blood"},{"issue":"7","key":"2026022411385138300_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026022411385138300_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026022411385138300_bib6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"2026022411385138300_bib7","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"10121","key":"2026022411385138300_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"The Lancet"},{"issue":"11","key":"2026022411385138300_bib9","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"20","key":"2026022411385138300_bib10","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026022411385138300_bib11","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1182\/blood-2023-181216","article-title":"Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma - a phase II clinical trial","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411385138300_bib12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood-2024-192939","article-title":"Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) phase II trial","volume":"144","author":"Jerkeman","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2026022411385138300_bib13","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023012424","article-title":"Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis","volume":"8","author":"Wang","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026022411385138300_bib14","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2023-174718","article-title":"Traverse: a phase 2, open-label, randomized study of acalabrutinib in combination with venetoclax and rituximab in patients with treatment-naive mantle cell lymphoma","volume":"142","author":"Hawkes","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2026022411385138300_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"2026022411385138300_bib16","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026022411385138300_bib17","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-024-47198-4","article-title":"Combination of acalabrutinib with lenalidomide and rituximab in relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial","volume":"15","author":"Park","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"2026022411385138300_bib18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjh.19951","article-title":"Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: results of the phase 1b open-label study (ACE-LY-003)","volume":"206","author":"Strati","year":"2025","journal-title":"Br J Haematol"},{"issue":"11","key":"2026022411385138300_bib19","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2352-3026(20)30291-X","article-title":"Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group","volume":"7","author":"Le Gouill","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2026022411385138300_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026022411385138300_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"14","key":"2026022411385138300_bib22","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2018-05-853499","article-title":"An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed\/refractory follicular B-cell lymphoma","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2026022411385138300_bib23","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood.2021013526","article-title":"Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study","volume":"139","author":"Bachy","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026022411385138300_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026022411385138300_bib25","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2026022411385138300_bib26","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2026022411385138300_bib27","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1182\/bloodadvances.2023009992","article-title":"Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma","volume":"7","author":"Phillips","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026022411385138300_bib28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2023-178509","article-title":"A prospective multicenter phase II study of orelabrutinib-lenalidomide-rituximab (OLR) in patients with untreated mantle cell lymphoma (MCL) in China (POLARIS Study): preliminary analysis on efficacy, safety, mutation spectrum and impact of mutation profiling on treatment responses","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026022411385138300_bib29","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026022411385138300_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026022411385138300_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood-2024-194357","article-title":"Ibrutinib, venetoclax plus CD20 monoclonal Ab provides very high MRD negativity in previously untreated MCL patients, initial results of OASIS II, a randomized phase 2 trial","volume":"144","author":"Le Gouill","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026022411385138300_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/bloodadvances.2023011920","article-title":"MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial","volume":"8","author":"Jerkeman","year":"2024","journal-title":"Blood Adv"},{"issue":"364","key":"2026022411385138300_bib33","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"28","key":"2026022411385138300_bib34","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026022411385138300_bib35","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2026022411385138300_bib36","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2026022411385138300_bib37","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/bloodadvances.2025015791","article-title":"Circulating tumor DNA determinants of response and outcome in relapsed\/refractory mantle cell lymphoma","volume":"9","author":"Meriranta","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026022411385138300_bib38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026022411385138300_bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026022411385138300_bib40","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1381\/2504325\/blooda_adv-2025-017760-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1381\/2504325\/blooda_adv-2025-017760-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:39:04Z","timestamp":1771951144000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1381\/548459\/MRD-driven-initial-therapy-of-acalabrutinib-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017760","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,17]]}}}